Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia

Blood (2025) 146 (25): 3086–3097.

https://doi.org/10.1182/blood.2025030177

Published: 2025

Includes: Supplemental data

Journal Articles

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 5657.

https://doi.org/10.1182/blood-2025-5657

Published: 2025

Journal Articles

Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice: A retrospective-prospective study by fondazione italiana linfomi (FIL)

Annamaria Frustaci, Pellegrino Musto, Francesco Autore, Francesco Piazza, Giulia Daghia, Angela Ferrari, Maura Nicolosi, Gioacchino Catania, Piero Galieni, Annarita Conconi, Michele Merli, Pier Luigi Zinzani, Monica Tani, Jacopo Olivieri, Samantha Deianira Dattoli, Luigi Marcheselli, Alessandra Tedeschi, Marzia Varettoni

Blood (2025) 146 (Supplement 1): 5360.

https://doi.org/10.1182/blood-2025-5360

Published: 2025

Journal Articles

TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FIL_biowm study of fondazione italiana linfomi

Blood (2025) 146 (Supplement 1): 5318.

https://doi.org/10.1182/blood-2025-5318

Published: 2025

Journal Articles

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Blood (2025) 146 (Supplement 1): 7427.

https://doi.org/10.1182/blood-2025-7427

Published: 2025

Journal Articles

Assessment of minimal residual disease with droplet digital polymerase chain reaction for BRAF V600E mutation in patients with hairy cell leukemia treated with purine analogs

Gianmarco Favrin, Chiara Varraso, Silvia Zibellini, Emilia Cappello, Virginia Ferretti, Sara Rattotti, Giulia Facchetti, Cristina Picone, Chiara Cavalloni, Martina La Fauci, Beatrice Cuniolo, Luca Arcaini, Marzia Varettoni

Blood (2025) 146 (Supplement 1): 1832.

https://doi.org/10.1182/blood-2025-1832

Published: 2025

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Blood (2025) 146 (Supplement 1): 5490.

https://doi.org/10.1182/blood-2025-5490

Published: 2025

Journal Articles

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfo, Persefoni Talimtzi, Maria Angelopoulou, Tomas Arpas, Laura Ballotta, Leonidas Benetatos, Ana Margarida Bertolo, Horia Bumbea, Maurizio Cavallari, Anastasia Chatzidimitriou, Dominik Chraniuk, Anna Christoforidou, Francesca Cibien, Antonio Cuneo, Maria Ilaria del Principe, Marina Deodato, Enrico Derenzini, Michael Doubek, Fabiana Esposito, Lucia Farina, Gianmarco Favrin, Isacco Ferrarini, Annamaria Frustaci, Andrea Galitzia, Massimo Gentile, Iulia Roxana Iancu, Vanessa Innao, krzysztof jamroziak, Elzbieta Kalicinska, Maria Kislova, Ioannis Kyriakou, Luca Laurenti, Enrico Lista, Javier Loscertales, Alexandros Machairas, Giorgia Marcato, Francesca Martini, Nilla Maschio, Eva Minga, Riccardo Moia, Roberta Murru, Maura Nicolosi, Jacopo Olivieri, Carolina Pavlovsky, Miguel Pavlovsky, Sara Pepe, Ernesto Perez Persona, Giuseppe Petruzzellis, Gian Matteo Rigolin, Alessandro Sanna, Marina Siakantaris, Paolo Sportoletti, Oana Stanca, Niki Stavrogianni, Tamar Tadmor, Annamaria Tomasso, Marzia Varettoni, Theodoros Vassilakopoulos, Eva Gimeno Vazquez, Candida Vitale, Mohamed Yassin, Mihnea Zdrenghea, Klaudia Zielonka, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2025) 146 (Supplement 1): 6287.

https://doi.org/10.1182/blood-2025-6287

Published: 2025

Journal Articles

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Blood (2025) 146 (Supplement 1): 5671.

https://doi.org/10.1182/blood-2025-5671

Published: 2025

Journal Articles

Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?

Marzia Varettoni, Emilia Cappello, Emanuela Boveri, Virginia Valeria Ferretti, Silvia Zibellini, Gianmarco Favrin, Chiara Varraso, Marco Lucioni, Cristina Picone, Giulia Vittoria Facchetti, Giovanni O. Palladini, Marco Paulli, Luca Arcaini

Blood (2024) 144 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2024-207850

Published: 2024

Journal Articles

Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 1854.

https://doi.org/10.1182/blood-2024-203053

Published: 2024

Journal Articles

Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

Blood (2024) 144 (Supplement 1): 3297.

https://doi.org/10.1182/blood-2024-198382

Published: 2024

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Journal Articles

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

Blood (2023) 142 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2023-184586

Published: 2023

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life

Blood (2023) 142 (Supplement 1): 6545.

https://doi.org/10.1182/blood-2023-188941

Published: 2023

Journal Articles

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Blood (2023) 142 (Supplement 1): 4646.

https://doi.org/10.1182/blood-2023-186182

Published: 2023

Journal Articles

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2023-181731

Published: 2023

Journal Articles

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

Blood (2023) 142 (Supplement 1): 6521.

https://doi.org/10.1182/blood-2023-174603

Published: 2023

Journal Articles

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Blood (2022) 140 (22): 2348–2357.

https://doi.org/10.1182/blood.2022016901

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice: A retrospective-prospective study by fondazione italiana linfomi (FIL)

TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FIL_biowm study of fondazione italiana linfomi

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Assessment of minimal residual disease with droplet digital polymerase chain reaction for BRAF V600E mutation in patients with hairy cell leukemia treated with purine analogs

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?

Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only